Pine River Capital Management L.P.

Q1 2017 13F Combination Report, Stock Holdings

Signature - Title
Tim O'Brien - General Counsel and Authorized Signatory
Location
Minnetonka, MN
Holdings as of
March 31, 2017
Value $
$2.08B
Num holdings
130
Date filed
5/15/2017, 12:14 PM
Description
A portion of the US holdings for this investor are reported in this report and a portion are reported by other reporting manager(s). Confidential Treatment Requested (one or more holding(s) omitted). The Form 13F report requires disclosure of the manager that files the report, the name and class of the security, the CUSIP code, the number of shares as of the end of the calendar quarter for which the report is filed, and the total market value. The market value column should not be used as a substitute for Assets Under Management (AUM), as it does not include cash held in accounts.
Previous filing
Q4 2016 - Feb 14, 2017
Next filing
Q2 2017 - Aug 14, 2017
Options Holdings
Showing stock holdings, see here for options holdings
Sym Weight Trade Impact Company Class Shares Change Activity Value Change $ Value $ * Price $ Shares Principal
Filing 2017 Q1 compared to 2016 Q4 by default.
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.

Confidential Treatment Requested. (The Manager has omitted from this public Form 13F one or more holding(s) for which it is requesting confidential treatment from the U.S. Securities and Exchange Commission pursuant to section 13(f) of the Exchange Act and rule 24b-2 thereunder)

Person Signing this Report on Behalf of Reporting Manager:

Name Title City, State Date
Tim O'Brien General Counsel and Authorized Signatory Minnetonka, Minnesota 5/15/2017

Other Included Managers (3):

Num Name Location File Number
1 Prisma Capital Partners LP 028-16926
2 American Beacon Advisors, Inc. 028-14511
3 BMO ASSET MANAGEMENT CORP. 028-16017